Core Viewpoint - The collaboration between 英矽智能 (Insilico Medicine) and 康哲药业 (Kanghong Pharmaceutical) in AI-driven drug development for central nervous system and autoimmune diseases is expected to enhance innovation and research capabilities in the pharmaceutical industry [1] Group 1: Company Developments - 英矽智能's stock price increased by over 9% to 73.45 HKD, reaching a new high of 74.80 HKD during trading [1] - The company is set to receive up to tens of millions of HKD in research funding for each of the projects under the collaboration agreement with 康哲药业 [1] Group 2: Industry Insights - 大摩 (Morgan Stanley) highlighted 英矽智能 as a leader in the AIDD (AI-Driven Drug Development) field, noting significant progress in both technology validation and application [1] - The execution capability of 英矽智能's chemical models supports a repeatable "1-to-N" innovation creation engine, with potential for further growth as biological model validations become evident [1]
英矽智能盘中涨超11%创新高 与康哲药业达成多个药物研发项目合作